PROBLEM TO BE SOLVED: To provide therapeutic treatment of diseases and disorders related to elevated lipoprotein levels.SOLUTION: Disclosed herein is a pharmaceutical composition comprising a PCSK9 inhibitor being an antibody or antigen-binding fragment thereof that specifically binds to PCSK9, which is used to increase transintestinal cholesterol excretion (TICE) in a patient suffering from or at risk of developing a cardiovascular disease or disorder selected from coronary artery disease, acute myocardial infarction, asymptomatic carotid atherosclerosis, stroke, and peripheral artery occlusive disease exhibiting reduced TICE. In certain embodiments, the pharmaceutical composition comprises 20-200 mg, preferably 50-150 mg of the PCSK9 inhibitor. In certain embodiments, the antibody or antigen-binding fragment thereof that specifically binds to PCSK9 comprises a heavy chain CDR and a light chain CDR of specific sequences.SELECTED DRAWING: None【課題】上昇したリポタンパク質レベルと関連する疾患及び障害の治療処置の提供。【解決手段】経腸コレステロール排泄（ＴＩＣＥ）の低下を示す、冠動脈疾患、急性心筋梗塞、無症候性頸動脈硬化症、脳卒中及び末梢動脈閉塞性疾患から選択される心血管疾患または障害を有するか、又はそれらを発症するリスクがある患者にＴＩＣＥを高めるのに使用するＰＣＳＫ９を特異的に結合する抗体又はその抗原結合性フラグメントである、ＰＣＳＫ９阻害剤を含む医薬組成物。ＰＣＳＫ９阻外剤を２０～２００ｍｇ、好ましくは５０～１５０ｍｇ、含有する医薬組成物。特定の配列を有する重鎖及び軽鎖ＣＤＲを含む、ＰＣＳＫ９に特異的に結合する抗体又は抗原結合性フラグメントを含む医薬組成物。【選択図】なし
